OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Tasadenoturev active in DIPG	1258
A new standard of care for advanced-stage urothelial carcinoma	922
From little subclones grow mighty oaks	860
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	850
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	843
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	726
Ecological management of the microbiota in patients with cancer	714
Hodgkin lymphoma: great progress with room for improvement	637
Novel ICI–TKI combination improves HCC outcomes	631
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	619
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	547
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	540
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	521
Current understanding and management of CAR T cell-associated toxicities	506
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	468
Gut microbiota in colorectal cancer development and therapy	461
The emerging roles of circRNAs in cancer and oncology	440
Contrasting results with second-line CAR T cells in large B cell lymphoma	400
Sacituzumab tirumotecan improves OS in mTNBC	382
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	378
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	369
Ponatinib superior to imatinib in Ph+ ALL	361
Mortality is similar with active monitoring	341
From ESMO 2022	340
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	333

Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	310
Humanized mouse models for immuno-oncology research	300
Understanding and overcoming multidrug resistance in cancer	258
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	254
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	251
Harnessing cytokines and chemokines for cancer therapy	249
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	248
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	245
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	245
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	244
Survival benefit with second-line combination in endometrial cancer	244
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	240
Craniospinal irradiation improves leptomeningeal metastasis control	239
Biomarkers for immunotherapy of hepatocellular carcinoma	231
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	229
Improving outcomes in patients with oesophageal cancer	221
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	221
Harnessing big data to characterize immune-related adverse events	214
Spatial landscapes of cancers: insights and opportunities	208
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	206
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	195
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	182
New CAPSTONE of SCLC therapy?	177
SHINE a light: frontline ibrutinib for MCL	175
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	170
Women with clinically node negative breast cancer can safely avoid axillary surgery	164
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	162
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	159
From ESMO 2023: advances in lung cancer	159
DREAMseq of therapy for BRAF-mutant melanoma	152
Prospective comparisons support the use of navigational bronchoscopy	151
Mitigating acute chemotherapy-associated adverse events in patients with cancer	150
Targeting chromosomal instability in patients with cancer	140
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	136
Long-term outcomes following CAR T cell therapy: what we know so far	130
Aumolertinib is effective in NSCLC	125
Circulating tumour DNA — looking beyond the blood	124
Response to neoadjuvant endocrine therapy complements recurrence score	116
Multiomics STEP up in correlative analysis of response to CAR T cells	113
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	113
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	113
From the ESMO Congress 2023	109
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	102
Enhancing immunotherapy with tumour-responsive nanomaterials	100
HAIC-FO improves outcomes in HCC	100
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	99
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	97
Newly approved cancer drugs in China — innovation and clinical benefit	96
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	96
Claudin 18.2 as a novel therapeutic target	95

Clinical implications of T cell exhaustion for cancer immunotherapy	95
Lung cancer in patients who have never smoked — an emerging disease	94
Combining CAR T cells effective in RRMM	93
Targeted biopsy reduces detection of clinically insignificant cancer	92
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	90
Two decades of advances in clinical oncology — lessons learned and future directions	84
Barriers in access to oncology drugs — a global crisis	83
T-DXd effective as second-line therapy in G/GEJ cancers	82
Second-line tarlatamab improves OS in SCLC	82
Translating biological insights into improved management of endometrial cancer	79
Less-frequent surveillance is noninferior to annual mammography	75
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	74
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	74
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	69
HSCT prolongs remission of high-risk CTCLs	66
BrECADD raises the bar in classical Hodgkin lymphoma	66
Nirogacestat effective in desmoid tumours	63
GPRC5D-CAR T cells active in MM	62
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	62
Promise with co-administration of CAR T cells	62
Efficacy of TILs confirmed	61
Cured but breathless: the growing burden of DIILD in cancer survivors	59
Thermal ablation is safer than resection of colorectal liver lesions	59
Promising OS with oncolytic virotherapy	58
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	57
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	57
Non-financial conflicts of interest	57
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	57
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	56
Exploiting bacteria for cancer immunotherapy	53
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	49
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	49
The current state of the art and future trends in RAS-targeted cancer therapies	47
Neoadjuvant pembrolizumab improves outcomes	43
Repotrectinib effective in ROS1-fusion-positive NSCLC	43
MSI-H/dMMR mCRC: ICIs in the first line?	42
Pembrolizumab tunes up chemotherapy in cervical cancer	40
LAG3 inhibition improves outcomes	39
Belzutifan is active in VHL-related cancers	37
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	36
KN046 shows tolerability and activity in TNBC	36
Problematic crossovers in cancer drug trials	35
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	33
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	33
The emerging roles of γδ T cells in cancer immunotherapy	31
Integrated MRI-guided radiotherapy — opportunities and challenges	31
CAR T cells induce durable remission of neuroblastoma	29
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	29
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	28
Axicabtagene effective in indolent NHL	27
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	26
National value-based pricing negotiation for oncology drugs — lessons from China	26
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	25
Personalizing adjuvant therapy for patients with colorectal cancer	23
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	23